Skip to Content

Clinical Trials Detail

A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers

Objective
This is a clinical trial of ponatinib that will be administered by mouth, which is investigational.
IRB Protocol Number
13-2002
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • Lung Cancer
Sponsor(s)
ARIAD Pharmaceuticals, Inc.
Contact
BREANNA PRITCHARD at 720-848-0498
or BREANNA.PRITCHARD@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your disease does not worsen, you do not have severe side effects, and the study remains open. // Eligibility criteria include but are not limited to 18 years or older with lung cancer.